Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...

A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating ...

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained ...

A type of immune cell targeting the Epstein-Barr virus may play a key role in driving multiple sclerosis (MS), a study found.

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

The Multiple Sclerosis Society of Bermuda today announced its plans for its 2026 Medical Symposium. A spokesperson said, “On Saturday, March 7th, 2026, the Society will hold its next Medical Symposium ...

Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...

Could plastic byproducts and forever chemicals found in drinking water cause your body to attack your own nervous system? New ...

Researchers at UC San Francisco have uncovered a new clue to how Epstein-Barr virus (EBV) could contribute to multiple ...

With this year's Read-a-Thon for kids, running through March, MS Canada hopes to raise CA$65,000 to support research and community programs.

BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug ...

MUSCAT: A recent study conducted at Sultan Qaboos University has shed new light on the psychological, cognitive and social ...